Glucosamine Sulphate and Ginkgo Biloba as Antifungal Activity for Treating Tinea Pedis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02882438|
Recruitment Status : Recruiting
First Posted : August 29, 2016
Last Update Posted : November 14, 2018
|Condition or disease||Intervention/treatment||Phase|
|Foot Infection Tinea Pedis||Drug: infected group Drug: control group||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Glucosamine Sulphate and Ginkgo Biloba for Treating Tinea Pedis|
|Study Start Date :||January 2016|
|Estimated Primary Completion Date :||September 2019|
|Estimated Study Completion Date :||October 2019|
Active Comparator: Infected group
A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Ginkgo Biloba in different dosage forms.
Drug: infected group
Ginkgo Biloba in different dosage forms
Other Name: Body Spray
Placebo Comparator: Control group
A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo without Ginkgo Biloba.
Drug: control group
placebo without Ginkgo Biloba
Other Name: placebo
- Assessment the antifungal activity of Ginkgo Biloba & Glucosamine [ Time Frame: six months ]Ginkgo Biloba and Glucosamine will be applied with infected patients even systemically or topically. The results will be compared with control groups to prove the Antifungal Activity.
- Stability test for different dosage forms [ Time Frame: three months ]Stability test will be studied for dosage forms. The test will carried out by standing the products on shelf life for three months. The stability test will be recorded using high performance liquid chromatography each thee days.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02882438
|Contact: Ahmed A. H. Abdellatif, phDfirstname.lastname@example.org|
|Assiut, Egypt, 71526|
|Contact: Ahmed AH Abdellatif, PhD|